Where Mirum Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Mirum Pharmaceuticals (NASDAQ:MIRM) has received mixed analyst ratings over the past three months, with 12 analysts offering a range of bullish to bearish perspectives. The average 12-month price target is $58.5, with a high of $77.00 and a low of $37.00. However, there has been a 17.89% decrease in the average price target, indicating a negative shift in sentiment. Analysts from firms like JMP Securities, Raymond James, HC Wainwright & Co., Cantor Fitzgerald, JP Morgan, Morgan Stanley, and Evercore ISI Group have provided various ratings and price target adjustments. Mirum Pharmaceuticals is a biopharmaceutical company with a focus on rare and orphan diseases, and its product Livmarli is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The company has shown a revenue growth rate of 154.13% as of September 30, 2023, but faces challenges with a net margin of -49.42% and a debt-to-equity ratio of 1.14.

January 11, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mirum Pharmaceuticals has received mixed analyst ratings and a decreased average price target, indicating a negative sentiment shift. Despite strong revenue growth, profitability and debt management remain concerns.
The negative shift in analyst sentiment and the decrease in the average price target suggest potential short-term downward pressure on MIRM's stock price. The strong revenue growth is a positive sign, but the concerns about net margin and debt management could overshadow the positive aspects and lead to bearish investor sentiment in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100